• About
  • Masthead
  • License Content
  • Advertise
  • Press Releases
  • Newsroom
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

Sign in
SUBSCRIBE
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • Medical Calculators
    • Clinical Guidelines
    • Physician Pay by Specialty
    • FDA Drug Approvals
    • RVU Search
    • ICD-10 Code Lookup
    • Drug Safety for Breastfeeding/Pregnancy
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
    • NPI Registry Lookup
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
2 Minute Medicine
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • Medical Calculators
    • Clinical Guidelines
    • Physician Pay by Specialty
    • FDA Drug Approvals
    • RVU Search
    • ICD-10 Code Lookup
    • Drug Safety for Breastfeeding/Pregnancy
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
    • NPI Registry Lookup
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
Sign in
SUBSCRIBE
2 Minute Medicine
Sign in
Subscribe
2 Minute MedicineFree on Google PlayGet
✦EvidencePulse™by 2 Minute Medicine3 reportsYou askedtop stroke trials 2026Synthesizing medical evidence...Top 2026 stroke trial results:OCEANIC — ischemic stroke: 6.2% vs 8.4%OPTION* — mRS 0–1: 43.6% vs 34.2%ORIENTAL* — mRS 0–2: 58.6% vs 46.6%*Higher sICH in intervention armsParticipants randomizedNOCEANIC12,327OPTION570ORIENTAL564Ask about guidelines or landmark trials...↑Try EvidencePulse™Ask the evidence. Get the signal.Try it now →
Home All Specialties Oncology

Neoadjuvant dostarlimab is a promising treatment option in locally advanced dMMR rectal cancer

byJohan PushaniandSze Wah Samuel Chan
June 13, 2022
in Oncology, Surgery
Reading Time: 2 mins read
Collage for anal disorders: a basin of warm water, a bowl of oats with prunes, a ring cushion and a water pitcher
Share on FacebookShare on TwitterShare on LinkedIn

1. All neoadjuvant dostarlimab patients had a clinical complete response and no patients needed any additional treatments at the study data cutoff.

2. There were no adverse events of grades 3 or higher. Most common adverse events of any grade were dermatitis, pruritus, fatigue, and nausea.

Evidence Rating Level: 2 (Good)

Study Rundown: Immune checkpoint inhibitors have had great success as a first-line treatment for patients with mismatch repair-deficient (dMMR) metastatic colorectal cancer. This study explored the efficacy and safety of neoadjuvant dostarlimab (a PD-1 inhibitor) on dMMR patients with locally advanced rectal cancer. Patients were only assigned to a treatment group. All patients who completed 6 months of dostarlimab had a clinical complete response. After 12 months of completion of dostarlimab treatment, no patients had evidence of recurrence or progressive diease. Pathological complete response was another endpoint but could not be evaluated as no patients had to undergo surgical resection. Most common adverse events of any grade were dermatitis, pruritus, fatigue, and nausea. There were no adverse events of grades 3 or higher. Limitations to this study include its small sample size and the fact it only observed dMMR patients, which comprise a very small subset of rectal cancer patients. A longer follow-up is also needed to assess the duration of response. The strengths of this study are that all patients had a clinical complete response and that dostarlimab may potentially omit both chemotherapy and surgery as treatments for this rare subtype of rectal cancer. Overall, dostarlimab shows tremendous promise for the treatment of surgically resectable rectal cancer and may change the current treatment landscape drastically.

Click to read the study in the NEJM (New England Journal of Medicine)

Relevant Reading: Advances and challenges in treatment of locally advanced rectal cancer

RELATED REPORTS

Interim global phase 2 AZUR-1 results show durable responses with dostarlimab monotherapy in untreated MSI-H/dMMR stage II/III locally advanced rectal cancer

FDA approves dostarlimab (Jemperli) for certain patients with locally advanced rectal cancer

In-Depth [prospective cohort]: This prospective phase II study included 16 dMMR patients with locally advanced rectal cancer. Of those 16 patients, only 12 have been enrolled for longer than 6 months. Clinical complete response after 6 months of dostarlimab was 100% (95% confidence interval [CI], 74 to 100). After 12 months of completion of dostarlimab treatment, none had recurrence of their cancer. By potentially bypassing surgery and chemotherapy, dostarlibumab may be able to negate all the negative health outcomes that can result from them, such as problems with fertility, sexual health, bowel and bladder. Since no resections were performed, pathological complete response was not evaluated. Most common adverse events of any grades were dermatitis (31% of patients), pruritus (25%), fatigue (25%), and nausea (19%). No adverse events of grades 3 or higher occurred. Overall, dMMR rectal showed high sensitivity to PD-1/PD-L1 blockade and further trials including more follow-up data will help shape the changes in approaching locally advanced rectal cancer.

Image: PD

©2022 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: dostarlimabprogrammed cell death protein 1 (PD-1)rectal cancer
Previous Post

Blended physical literacy interventions may improve physical literacy in children

Next Post

Trastuzumab deruxtecan is a treatment option for pre-treated HER2-low metastatic breast cancer

RelatedReports

Immunotherapy collage: an immune T cell meeting a cancer cell, Y-shaped antibodies and a small key on teal paper
Gastroenterology

Interim global phase 2 AZUR-1 results show durable responses with dostarlimab monotherapy in untreated MSI-H/dMMR stage II/III locally advanced rectal cancer

November 20, 2026
An illustration depicting the colon with IV bags on either side, symbolizing sequential therapy paths in colorectal cancer treatment.
Gastroenterology

FDA approves dostarlimab (Jemperli) for certain patients with locally advanced rectal cancer

October 29, 2026
Lymphoma treatment collage: an older man with a gray beard in a quarter-zip sweater beside five round white blood cells
Chronic Disease

Penpulimab and lenalidomide in combination with standard of care chemoimmunotherapy demonstrates promising safety and efficacy in diffuse large B-cell lymphoma

February 19, 2026
Preoperative bilateral breast imaging may reduce contralateral cancer recurrence
Oncology

Sacituzumab govitecan plus pembrolizumab improves survival in advanced triple-negative breast cancer

January 28, 2026
Next Post
Age and number of islet autoantibodies associated with diabetes risk

Trastuzumab deruxtecan is a treatment option for pre-treated HER2-low metastatic breast cancer

ABCD2 Score: Predicting Early Stroke Risk After Transient Ischemic Attack (TIA) [Classics Series]

The EAST-AFNET 4 trial: Early rhythm control therapy for atrial fibrillation [Classics Series]

Forearm parathyroid reimplantation may be effective in preventing hypoparathyroidism

Primary hyperparathyroidism associated with an increased risk of fractures and cardiovascular events

✦ EvidencePulse™ by 2 Minute Medicine 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... Try EvidencePulse™ Get the signal. Try it now → Physician-trained medical AI by 2 Minute Medicine

2MM+ All Access

Full details →
$4.99 /month

3-day free trial · cancel anytime

  • ✓100+ physician-written reports
  • ✓EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Long-term use of mometasone (Asmanex) in adults with sickle cell disease without formal diagnosis of asthma may worsen disease activity
  • Few patients had ED lumbar CT or MRI within 30 days after low-acuity back-pain radiography at urgent care centers
  • A 34-circular RNA blood signature predicted Alzheimer’s disease progression and improved prediction when combined with pTau217
License Content
Terms of Use | Disclaimer
Cookie Policy

Get the app

Read 2 Minute Medicine on iPhone, iPad and Android.

Download on the App StoreGet it on Google Play
QR code for www.2minutemedicine.com/app
On a computer? Scan this with your phone’s camera.
2MM+ All Access Full details →

The medical literature, distilled daily.

Monthly plan selected: $4.99 /month.

$4.99/month

3-day free trial · cancel anytime

Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

Yearly plan selected: $49.90 /year.

$49.90/year

2 months free

Start 3-day free trial

Then $49.90/year.

Membership benefits

  • ✓100+ new physician-written study summaries monthly, 12,000+ searchable
  • ✓AI EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
  • ✓FDA drug approvals + clinical calculators

Already a member? Sign in

  • Get the app
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • Medical Calculators
    • Clinical Guidelines
    • Physician Pay by Specialty
    • FDA Drug Approvals
    • RVU Search
    • ICD-10 Code Lookup
    • Drug Safety for Breastfeeding/Pregnancy
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
    • NPI Registry Lookup
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
No Result
View All Result

© 2026 2 Minute Medicine, Inc. - Physician-written medical news.